NLRX1 and inflammatory bowel disease: The abrogation of increased inflammation and disease severity with Cay10591 suggests that NLRX1 might aid in the activation of SIRT1 to control epithelial barrier homeostasis and prevention of intestinal inflammation in response to altered permeability during IBD.